Liability and health books are growth drivers of China’s non-life market: Fitch
July 14 2022 by Karen Lai
-
Amit Ganorkar returns to Tata AIG as managing director and CEO
- November 12
Ganorkar, who was previously the chief operating officer of the Indian insurer, takes over from Neelesh Garg, who resigned last month.
-
AIG Korea takes Aon’s Han Bit Kim as financial lines underwriter
- November 12
Seoul-based Kim was most recently manager for the broker focused on the dynamics of large complex insurance policies.
-
China’s ZhongAn’s operating performance is subject to investment volatility, business risk: AM Best
- November 11
The rating agency affirms financial strength rating of A- (excellent) and long-term issuer credit rating of “a-” (excellent) to the carrier with a stable outlook.
-
RJC Insurance Brokers launches in New South Wales
- November 11
The broker will be led by managing directors Russell and Julie Chegwyn and will place and manage covers for businesses in industries ranging from rail construction & maintenance to civil construction.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
